Ipriflavone regulates the differentiation and biosynthetic properties of human bone marrow stromal osteoprogenitor cells (BMC) by enhancing the expression of certain important matrix proteins and promoting the mineralization process. Treatment with ipriflavone at a dose of 10 μM significantly inhibited glycation end product (AGE)-enhanced bone resorption in cultured mouse undifferentiated bone cells. In addition, IprChemicalbookiflavone treatment can effectively enhance calcium absorption in duodenal cells. Ipriflavone dose-dependently inhibits the proliferation and DNA synthesis of MDA-231 cells and blocks ligand-induced phosphorylation of Tyr845 in EGFR. Treatment with ipriflavone at a dose of 50 μM did not induce apoptosis in MDA-231 cells.